Ratnakar Reddy Kuchukulla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ratnakar Reddy Kuchukulla has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Banda Narsaiah
Fluoroorganic division CSIR-Indian Institute of Chemical Technology, Tarnaka Hyderabad- 500007 India
3 shared publications - Chityala Ganesh Kumar
Medicinal Chemistry and Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India
2 shared publications G. Jitender Dev
Fluoroorganic Division, (AcSIR)CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500007, India
2 shared publicationsLihong Zhou
College of Environment and Ecology Chengdu University of Technology 610059 Chengdu China
2 shared publicationsNorio Shibata
Nagoya Institute of Technology, Gokiso, Showa-ku
2 shared publications- Qingle Zeng
Chengdu University of Technology
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Oxidative ArylSF4-tetrafluoroethylation to N-hydroxydicarboximides via in situ generated Silver intermediate from silver(I) fluoride.
An efficient and streamlined protocol for the ArylSF4-tetrafluoroethylation of N-hydroxyimides has been developed utilizing an in situ generated silver- (1,2,2,2-tetrafluoro-1-(SF4Aryl)ethyl reagent. While traditional methods rely heavily on common fluoroalkylating agents, Aryl-SF4 containing polyfluoroalkylating reagents remain very rare. Herein, we generating a highly reactive silver-tetrafluoroethyl(SF4Aryl) species in situ, followed by its immediate oxidative radical reaction with a diverse range of N-hydroxyimides. Under optimized reaction conditions, using N-Bromosuccinimide as the terminal oxidant, the corresponding Aryl-SF4 containing tetrafluoroethylated products were obtained in moderate to good yields (up to 69 %). This transition-metal-promoted tandem process exhibits broad substrate scope, high functional group tolerance, and eliminates the need for the isolation of unstable organometallic intermediates. Given the high demand for fluorinated motifs in medicinal chemistry and materials science, this operational simplicity offers a powerful, robust strategy for late-stage SF4 containing polyfluoroalkylation.
- 24 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessOxidative ArylSF4-tetrafluoroethylation to N-hydroxydicarboximides via in situ generated Silver intermediate from silver(I) fluoride.
An efficient and streamlined protocol for the ArylSF4-tetrafluoroethylation of N-hydroxyimides has been developed utilizing an in situ generated silver- (1,2,2,2-tetrafluoro-1-(SF4Aryl)ethyl reagent. While traditional methods rely heavily on common fluoroalkylating agents, Aryl-SF4 containing polyfluoroalkylating reagents remain very rare. Herein, we generating a highly reactive silver-tetrafluoroethyl(SF4Aryl) species in situ, followed by its immediate oxidative radical reaction with a diverse range of N-hydroxyimides. Under optimized reaction conditions, using N-Bromosuccinimide as the terminal oxidant, the corresponding Aryl-SF4 containing tetrafluoroethylated products were obtained in moderate to good yields (up to 69 %). This transition-metal-promoted tandem process exhibits broad substrate scope, high functional group tolerance, and eliminates the need for the isolation of unstable organometallic intermediates. Given the high demand for fluorinated motifs in medicinal chemistry and materials science, this operational simplicity offers a powerful, robust strategy for late-stage SF4 containing polyfluoroalkylation.
- Open Access
- 20 August 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Synthesis of novel 2-(tetrafluoro(1,2,2-trifluorovinyl)- λ6-sulfaneyl)Aryls and their applications
This study introduces a novel method for the synthesis of 2-(tetrafluoro(1,2,2-trifluorovinyl)- λ6-sulfaneyl)Aryls, followed by an exploration of their applications. Specifically, (tetrafluoro(1,2,2-trifluorovinyl)- λ6-sulfaneyl)Aryls were synthesized from Aryl-SF4Cl via radical addition to trifluoroethylene in presence of 2,2'-Azobis(2,4-dimethylvaleronitrile) (ADVN) catalyst, followed by the elimination of HCl. Furthermore, the synthetic utility of this novel compound is demonstrated.
- 20 August 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessSynthesis of novel 2-(tetrafluoro(1,2,2-trifluorovinyl)- λ6-sulfaneyl)Aryls and their applications
This study introduces a novel method for the synthesis of 2-(tetrafluoro(1,2,2-trifluorovinyl)- λ6-sulfaneyl)Aryls, followed by an exploration of their applications. Specifically, (tetrafluoro(1,2,2-trifluorovinyl)- λ6-sulfaneyl)Aryls were synthesized from Aryl-SF4Cl via radical addition to trifluoroethylene in presence of 2,2'-Azobis(2,4-dimethylvaleronitrile) (ADVN) catalyst, followed by the elimination of HCl. Furthermore, the synthetic utility of this novel compound is demonstrated.
- Open Access
- 23 August 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (9) , 1041
Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
HER2-positive (HER2+) breast cancer is defined by HER2 oncogene amplification on chromosome 17q12 and accounts for 15–20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. However, more than 50% of the patients respond poorly to trastuzumab, illustrating that novel therapy is warranted to overcome the resistance. We previously reported that in the majority of HER2+ breast-cancer patients, CDK12 is co-amplified on 17q12 and involved in developing tumors and trastuzumab resistance, proposing CDK12 as a potential drug target for HER2+ breast cancers. Here, we designed and synthesized novel 2,6,9-trisubstituted purines as potent CDK12 inhibitors showing strong, equipotent antiproliferative activity against trastuzumab-sensitive HER2+ SK-Br3 cells and trastuzumab-resistant HER2+ HCC1954 cells (GI50 values < 50 nM) both of which express a high level of CDK12. Two potent analogue 30d and 30e at 40, 200 nM greatly downregulated the levels of cyclinK and Pol II p-CTD (Ser2), as well as the expression of CDK12 downstream genes (IRS1 and WNT1) in a dose-dependent manner. We also observed structure-property relationship for a subset of potent analogues, and found that 30e is highly stable in liver microsomes with lack of CYP inhibition. In addition, 30d exhibited a synergy with trastuzumab in the both cells, suggesting that our inhibitors could be applied to alleviate trastuzumab-resistance of HER2+ breast cancers and escalate the efficacy of trastuzumab as well. Our study may provide insight into developing a novel therapy for HER2+ breast cancers.
- 23 August 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (9) , 1041
Open AccessNovel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
HER2-positive (HER2+) breast cancer is defined by HER2 oncogene amplification on chromosome 17q12 and accounts for 15–20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. However, more than 50% of the patients respond poorly to trastuzumab, illustrating that novel therapy is warranted to overcome the resistance. We previously reported that in the majority of HER2+ breast-cancer patients, CDK12 is co-amplified on 17q12 and involved in developing tumors and trastuzumab resistance, proposing CDK12 as a potential drug target for HER2+ breast cancers. Here, we designed and synthesized novel 2,6,9-trisubstituted purines as potent CDK12 inhibitors showing strong, equipotent antiproliferative activity against trastuzumab-sensitive HER2+ SK-Br3 cells and trastuzumab-resistant HER2+ HCC1954 cells (GI50 values < 50 nM) both of which express a high level of CDK12. Two potent analogue 30d and 30e at 40, 200 nM greatly downregulated the levels of cyclinK and Pol II p-CTD (Ser2), as well as the expression of CDK12 downstream genes (IRS1 and WNT1) in a dose-dependent manner. We also observed structure-property relationship for a subset of potent analogues, and found that 30e is highly stable in liver microsomes with lack of CYP inhibition. In addition, 30d exhibited a synergy with trastuzumab in the both cells, suggesting that our inhibitors could be applied to alleviate trastuzumab-resistance of HER2+ breast cancers and escalate the efficacy of trastuzumab as well. Our study may provide insight into developing a novel therapy for HER2+ breast cancers.
- 18 May 2020
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2020 (26) , 4004-4008
Synthesis of Aryl(chalcogen‐heteroaryl)methyl Sulfones via Sulfuric Acid‐Promoted Three‐Component Reaction in Water
A facile and efficient three‐component reaction in the presence of Brønsted acid in water was developed to synthesize aryl(chalcogen‐heteroaryl)methyl sulfones in good to very high yields with broad substrate scope. Our protocol is eco‐friendly, metal free, and atom economic. The sulfone products may be efficiently transformed into a bactericidal agent analogue and an aryl heteroaryl ketone.
- 18 May 2020
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2020 (26) , 4004-4008
Synthesis of Aryl(chalcogen‐heteroaryl)methyl Sulfones via Sulfuric Acid‐Promoted Three‐Component Reaction in Water
A facile and efficient three‐component reaction in the presence of Brønsted acid in water was developed to synthesize aryl(chalcogen‐heteroaryl)methyl sulfones in good to very high yields with broad substrate scope. Our protocol is eco‐friendly, metal free, and atom economic. The sulfone products may be efficiently transformed into a bactericidal agent analogue and an aryl heteroaryl ketone.
- 14 October 2019
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 21 (21) , 5808-5812
A recyclable Amberlyst-15-catalyzed three-component reaction in water to synthesize diarylmethyl sulfones
A recyclable Amberlyst-15-catalyzed three-component reaction in water was developed to synthesize asymmetric diarylmethyl sulfones in good to excellent yields with a wide substrate scope. Asymmetric diarylmethyl sulfones were prepared via C–C and C–S bond formation in a single step between easily available aryl/alkyl aldehydes, sodium aryl/alkyl sulfinates and tri/dimethoxybenzenes.
- 14 October 2019
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 21 (21) , 5808-5812
A recyclable Amberlyst-15-catalyzed three-component reaction in water to synthesize diarylmethyl sulfones
A recyclable Amberlyst-15-catalyzed three-component reaction in water was developed to synthesize asymmetric diarylmethyl sulfones in good to excellent yields with a wide substrate scope. Asymmetric diarylmethyl sulfones were prepared via C–C and C–S bond formation in a single step between easily available aryl/alkyl aldehydes, sodium aryl/alkyl sulfinates and tri/dimethoxybenzenes.
- 11 December 2017
- Published by Wiley in ChemistrySelect
- Vol. 2 (35) , 11545-11547
Regioselective Synthesis of 2‐(Trifluoromethyl)‐3‐ethoxycarbonyl‐4‐(2‐oxo‐2‐arylethyl)‐4 H ‐chromene Derivatives by [3, 3] Sigmatropic Rearrangement
A new and an efficient method has been developed to synthesize ethyl 4‐(2‐oxo‐2‐arylethyl)‐2‐(trifluoromethyl)‐4 H ‐chromene‐3‐carboxylate derivatives 3 from 2 H ‐chromene 1 and aryl acetylene 2 through [3, 3] sigmatropic rearrangement in presence of catalytic amount of BF 3 . OEt 2 (10 mol %).
- 11 December 2017
- Published by Wiley in ChemistrySelect
- Vol. 2 (35) , 11545-11547
Regioselective Synthesis of 2‐(Trifluoromethyl)‐3‐ethoxycarbonyl‐4‐(2‐oxo‐2‐arylethyl)‐4 H ‐chromene Derivatives by [3, 3] Sigmatropic Rearrangement
A new and an efficient method has been developed to synthesize ethyl 4‐(2‐oxo‐2‐arylethyl)‐2‐(trifluoromethyl)‐4 H ‐chromene‐3‐carboxylate derivatives 3 from 2 H ‐chromene 1 and aryl acetylene 2 through [3, 3] sigmatropic rearrangement in presence of catalytic amount of BF 3 . OEt 2 (10 mol %).
- 1 August 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (15) , 2943-2947
Synthesis of novel amide functionalized 2H-chromene derivatives by Ritter amidation of primary alcohol using HBF4·OEt2 as a mild and versatile reagent and evaluation of their antimicrobial and anti-biofilm activities
- 1 August 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (15) , 2943-2947
Synthesis of novel amide functionalized 2H-chromene derivatives by Ritter amidation of primary alcohol using HBF4·OEt2 as a mild and versatile reagent and evaluation of their antimicrobial and anti-biofilm activities
- 1 April 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (7) , 1661-1663
Synthesis of novel 1,2,3-triazole/isoxazole functionalized 2H-Chromene derivatives and their cytotoxic activity
- 1 April 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (7) , 1661-1663
Synthesis of novel 1,2,3-triazole/isoxazole functionalized 2H-Chromene derivatives and their cytotoxic activity